Objective: Treatment with renin angiotensin aldosterone system (RAAS) blockade including angiotensin-converting enzyme inhibitors (ACEis) and angiotensin II receptor blockers (ARBs) have been shown to improve clinical outcomes. However, recent contrasting evidence regarding the dual RAAS blockade has also been presented. Very few studies have investigated the effectiveness of this dual blockade among diabetic nephropathy (DN) patients in association with albuminuria or proteinuria.
Background
Type 2 diabetes mellitus is a debilitating disease and the leading cause of end-stage renal disease worldwide [1] . Earlier evidence suggests that treatment with renin angiotensin aldosterone system (RAAS) inhibitors, including angiotensin-converting enzyme inhibitors (ACEis) and angiotensin II receptor blockers (ARBs), have been shown to improve clinical outcomes among diabetic patients with hypertension, while also reducing the incidence of microalbuminuria in patients with normoalbuminuria [2, 3] , the progression to overt proteinuria in patients with microalbuminuria [4] [5] [6] , and the development of end-stage renal disease in patients with overt nephropathy [1] .
In addition, available data suggests that a dual blockade of RAAS is not currently feasible among diabetic patients with diabetic nephropathy (DN). This does not mean that in future, a dual blockade (ACEi plus ARBs) should not be used in these patients, but that this therapeutic approach should be tested among selected diabetic populations to identify subgroups of patients with whom the desired nephro-and cardio-protection are achieved without increase in side effects (10) . The results of these previous studies revealed that ONTARGET, ALTITUDE, and VA NEPHRON-D do not allow the formulation of definitive considerations on the role of a dual blockade of RAAS with ACEi and ARBs among diabetic patients with microalbuminuria or proteinuria. This is because they were heterogeneous studies with short follow-up durations and weak end-points [10] . Although a study conducted by Elrggal et al. was selective and somewhat biased, the authors make compelling arguments that cast serious doubt over the strength of the evidence upon which the current guidelines are based, favoring the use of dual RAAS blockade among DKD patients [11] .
Regarding albuminuria, a few studies suggest that albuminuria should not be considered as a target for treatment, but instead a surrogate marker of DKD progression, as it is unknown whether the adverse effects of combination therapy will offset any benefit [11, 12] . It was also suggested that reduced albuminuria does not always translate to a decrease in cardiovascular and renal morbidity. However, dual therapy carries an increased risk [10] .
Over the past five years, interventions with a dual RAAS blockade may have improved or shown positive or negative effects among diabetic patients. As such, there is little evidence that evaluates the dual RAAS blockade therapies among DN patients with albuminuria or proteinuria. Therefore, this review attempts to fill this research void by providing a transparent overview of dual RAAS blockade and monotherapies in modern day medicine.
Research Design and Methods
A systematic review and meta-analysis were conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [13] .
Data Sources and Searches
A review of randomized controlled trials (RCT) studies (n = 45) reporting on the dose response analysis among DN patients using dual RAAS inhibitors including both ACEi and ARBs or other monotherapies over a 25-year period (1993 -2017) was performed. We felt that it was imperative to also include RCTs using monotherapy, in order to provide a transparent overview of the therapeutic effect among DN patients. The following databases were searched: NHS evidence, EMBASE, Medline and PubMed, Google Scholar, and the Cochrane Library. The search items were based on established terminology using Cochrane definitions where possible and were "diabetic nephropathy" and "renin angiotensin aldosterone system;" "RAS/RAAS blockade" and "albuminuria;" "RAS/RAAS blockade" and "proteinuria."
The titles and/or abstracts were reviewed to exclude any clearly irrelevant studies. The full texts of the remaining studies were then retrieved and read in full, independently, to determine whether the studies met inclusion criteria. The reference lists of studies that examine the topic of interest were checked for additional publications.
Criteria for inclusion in the review
Abstracts were considered eligible for full manuscript data extraction if the study met all the following criteria: a) they reported an association or dissociation of a dose response analysis between either dual RAAS blockade or monotherapy and DN; b) the sample consisted of adults (>18 years of age); and c) the study design was cross-sectional or randomized controlled trials (RCTs). Studies that solely consisted of patients with type 1 or 2 diabetes (without nephropathy, albuminuria, or proteinuria) were not included. Our inclusion criteria revealed 45 studies of DN patients with either albuminuria or proteinuria.
Data extraction
Using a standardized data extraction sheet, the following information (if available) was extracted and recorded from the studies: authors; year of publication; country of origin; study design; total sample size of participants; methods of assessment/ experiment; outcomes; effective treatments. If multiple risk estimates were presented in a given manuscript, the unadjusted estimate was selected for the primary meta-analysis as some studies were adjusted for prominent confounding variables, while others were not, rendering a direct comparison of estimates to be questionable.
Quality assessment
The PRISMA guidelines for RCTs (13) were used to examine the quality of the studies. These include adequacy of study design (RCT with an adequate control group); recruitment of sample; ascertainment of diabetes, albuminuria and RAAS inhibitors; and control for co-founding variables, such as BP, and estimated glomerular filtration rates (eGFR). The quality of the studies was not summarized with a score, as this approach has been criticized for allocating equal weight to different aspects of methodology [14] , but a formal assessment of the risk of bias and strength of evidence according to the Agency for Healthcare Research and Quality (AHRQ) guidelines was conducted [15] . A study was considered to be of high quality if the study design was prospective in nature; consecutive or a random sampling method was used; and cofounders for DN, albuminuria and proteinuria, systolic BP (SBP), diastolic BP (DBP), and eGFR were accounted for.
Data Synthesis and Analysis
The primary outcome analyzed was the mean difference in percent reduction in proteinuria and albuminuria between the combination therapy and monotherapy groups. In some studies, proteinuria and albuminuria outcome data were presented as the geometric mean and 95% confidence interval (CI). In studies which had two monotherapy comparator arms (eg. ACEi or ARB, enalapril or losartan, telmisartan or valsartan, spironolactone or control), the average of the means and standard errors of the two arms was utilized. Secondary outcomes included changes in SBP, DBP, and GFR.
We fitted a random effects model to the study data as it includes estimates taken from a series of independently performed studies. We interpreted I2 results as low, moderate, and high heterogeneity represented by 0-25%, 26-50%, and >50%, respectively. Forest plots were created with STATA 14.2 (StataCorp (College Station, Texas USA) and are reported with standard errors (SE) and 95% confidence intervals for mean differences.
Results

Study selection
The flowchart for study inclusion is shown in Figure 1 . The literature search resulted in 987 studies. After review of their titles and abstracts, 152 studies met the initial inclusion criteria and were retrieved for full text review. Of these, 107 studies were excluded from the systematic review as they no longer met the inclusion criteria. A total of 45 studies were included in the systematic review, and the extracted data are summarized in Table 1 . The risk of bias of the studies (n = 18) was included in the meta-analysis using the Cochrane assessment tool ( Table 2) . Compared the effect of aliskiren, a direct renin inhibitor (DRI), with that of angiotensin receptor blockers (ARB) on albuminuria and urinary excretion of angiotensinogen DRI is not superior to ARB in the reduction of urinary excretion of albumin and angiotensinogen.
Qualitative summary
DRI No
Kato et al. [17] 2015 Japan Tested the separate and combined effects of sodium restriction and hydrochlorothiazide (50 mg daily), added to lisinopril 40 mg daily on albuminuria (primary endpoint).
Sodium restriction is an effective non-pharmacological intervention to increase RAAS blockade efficacy in type 2 DN.
Sodium restriction Yes
Fernández-Juárez et al. [20] 2013 Spain RCT 103
Compared the efficacy of combining an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker with the efficacy of each drug in monotherapy to slow the progression of established DN
(OH) vitamin D deficiency is
independently associated with a higher risk of the composite outcome in patients with type II DN.
(OH) vitamin D deficiency
Yes Imai et al. [1] 2013 Japan RCT and post-hoc analysis 563
Examined the effects of olmesartan on renal and cardiovascular outcomes in the presence or absence of an ACEi.
In DN patients, olmesartan significantly reduced proteinuria, independent of ACEi treatment and cardiovascular outcome.
Olmesartan Yes
Karalliedde et al. [21] 2013 England RCT 76
Patients with type 2 DM and DKD (with albuminuria and serum creatinine <1.7 mg/dl) were studied at baseline and at 24 weeks after randomization to valsartan/ hydrochlorothiazide (n=37) or amlodipine (n=39) treatment.
Treatment with RAS blockers, valsartan, is associated with an increase in soluble Klotho, which may contribute to BP-independent cardiorenal benefits.
Valsartan Yes
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Mann et al. [22] 2013 Germany RCT 9628
Examined the effects of addition of an ACE inhibitor (ramipril) to an ARB (telmisartan) for a mean follow-up of 56 months in people with diabetes A combination of ACEi and ARB does not increase strokes or alter other major cardiovascular or renal events in patients with diabetes, irrespective of the presence of nephropathy.
ACEi and ARB Yes
Pruijm et al. [23] 2013 Switzerland Prospective randomized 2-way cross over study 12 Patients with (micro)albuminuria and/or hypertension underwent blood oxygenation level-dependent magnetic resonance imaging at baseline, after one month of enalapril (20 mgqd), and candesartan (16 mgqd) .
RAS blockade does not seem to increase renal tissue oxygenation in type 2 diabetes mellitus hypertensive patients.
RAAS Blockade No
Ghorbani et al. [24] 2012 Iran Double-blinded clinical trial 100
Assessed the additive effect of pentoxifylline on reduction of proteinuria among patients with type 2 DM under blockade of angiotensin system.
Pentoxifylline can significantly provide additive antiproteinuric effect and slow the decrease in GFR among patients with type 2 DM under blockade of angiotensin system.
Pentoxifylline Yes
Fernández-Juárez et al. [25] 2013 Spain RCT 133
Compared the efficacy of combining the angiotensin-converting enzyme inhibitor lisinopril and the angiotensin II receptor blocker irbesartan with that of each drug in monotherapy in slowing the progression of type 2 DN.
There was no benefit of the combination of lisinopril and irbesartan compared to either agent alone at optimal high doses on the risk of progression of type 2 DN.
Lisinopril/ Irbesartan No
Fallahzadeh et al. [26] 2012 Iran
Randomized, double-blind, placebo-controlled, 2-arm parallel trial.
60
UACR and urinary and serum levels of TNF-α (tumor necrosis factor α), malondialdehyde (MDA), and TGFβ (transforming growth factor β) at baseline and the end of the treatment phase.
Silymarin reduces urinary excretion of albumin, TNF-α, and MDA in patients with DN and may be considered as a novel addition to the anti-DN armamentarium.
Silymarin Yes
Rasi Hashemi et al. [27] 2012 Iran RCT 70
Randomly divided into two groups and were treated with losartan, 25 mg, twice per day, with and without N-acetyl cysteine (NAC), 600 mg twice daily (study and control groups, respectively; 35 patients in each group).
Angiotensin receptor blockers reduced proteinuria due to DN, and this study failed to detect additional effect when NAC was combined with these medications.
ARB Yes
Kohan et al. [28] 2011 USA randomized, double-blind, placebo-controlled trial 89 Randomly assigned subjects with EGFR >20 ml/min per 1.73 m(2) and a urinary albumin-to-creatinine ratio (UACR) of 100 to 3000 mg/g to placebo or atrasentan (0.25, 0.75, or 1.75 mg daily) for 8 weeks
Atrasentan, at the doses tested, is generally safe and effective in reducing residual albuminuria and may ultimately improve renal outcomes in patients with type 2 DN. Krairittichai et al. [34] 2009 Thailand RCT 80
Type 2 diabetic patients with urine protein/creatinine (upcr) > 0.5 gm/gm and hypertension who received maximal recommended dose of ACE inhibitors (Enalapril 40 mg/day) over three months were randomized to two groups.
Adding maximal recommended dose of ARB with maximal recommended dose of ACE inhibitors in type 2 diabetic patients can reduce proteinuria more than ACE inhibitors alone.
Dual and Enalapril Yes
Ogawa et al. [35] 2008 Japan RCT 38
The patients were randomly assigned to two groups, an azelnidipine AZ group (n=21, 16 mg/d) and a nifedipine-CR (NF) group (n=17, 40 mg/d).
A combination therapy of RAS inhibitors and AZ is an effective therapeutic modality for decreasing not only blood pressure but also inflammations and oxidative stresses.
Dual and AZ Yes
Galle et al. [36] 2008 Germany multicenter, double-blind, prospective, parallel-group non-inferiority study 885
Patients with T2D, proteinuria (> or: 900 mg/24 h) and serum creatinine (< or: 3.0 mg/dl) were randomized to once-daily telmisartan 80 mg or valsartan 160 mg
In patients with T2D, hypertension and overt nephropathy, the renoprotection afforded by telmisartan and valsartan appears similar; study was unable to show an effect beyond that due to BP control.
Telmisartan and Valsartan
No Wang et al. [37] 2008 China RCT 71
In 37 patients, angiotensin receptor blocker (ARB) was added (the combination group); ACEi alone was continued in the other 34 (the control group) at 0 to 12 weeks.
Urinary expression of synaptopodin was lower after 12 weeks of ACEi and ARB combination therapy.
Dual Yes
Yoneda et al. [38] 2007 Japan RCT 95
Patients were treated with candesartan (8 mg/day, n: 47) or valsartan (80 mg/day, n: 48) for 15 months. 9 patients who exhibited aldosterone breakthrough after treatment with ARB were placed on spironolactone (25 mg/day) for 3 months.
Aldosterone blockade therapy may be effective in preventing renal injury in hypertensive patients with aldosterone breakthrough.
ABT Yes
Eijkelkamp et al. [39] 2007 Netherlands RCT 1428 This study investigated the adequacy of this approach in 1428 patients with hypertension and DN from the placebocontrolled Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study Antihypertensive treatment that is aimed at improving renal outcomes in patients with DN may therefore require a dual strategy, targeting both SBP and albuminuria reduction.
Dual Yes
Kurokawa et al. [40] 2006 Japan double-blind, randomized study 1513
This study compared losartan (50 to 100 mg once daily) with placebo.
In Japanese patients with type 2 diabetes and nephropathy, losartan offers renal protection and is generally well tolerated.
Losartan Yes
Stevanovic et al. [41] 2005 USA RCT 81
Forty-four consecutively enrolled Type 1 diabetic patients (28.2+/-1.5 years) and 37 normal subjects (37+/-2.6 years) in high salt balance were given 25 mg of captopril and 16 mg of candesartan p.o. On consecutive days.
Renin response to ACEi and ARB confirms activation of the RAS in diabetic patients.
Dual Yes
Song et al. [42] 2006 Korea prospective double-blinded randomized crossover trial 21
Trial consisting of three 16-week treatment periods with ramipril alone (10 mg/day), candesartan alone (16 mg/day), and ramipril (5 mg/day) plus candesartan (8 mg/day) combination therapy.
The dual blockade of RAS with low-dose ramipril plus candesartan was found to be safe and offered additive benefits with respect to reducing proteinuria and urinary TGF-β1 excretion.
Matos et al. [43] 2005 Brazil RCT 20 Patients with non-nephrotic proteinuria (0.5 -3.0 g/day) and estimated creatinine clearance > or: 40 ml/min/1.73 m2 were randomly assigned to be treated with perindopril 8 mg/day (Per), irbesartan 300 mg/day (Irb) or a combination of both
Only combined therapy with irbesartan plus perindopril concurrently reduces plasma aldosterone, proteinuria, and urinary TGF-β1.
Pohl et al. [44] 2005 USA double-blind, placebo-controlled trial 1590
Effects of baseline and mean follow-up systolic BP (SBP) and diastolic BP and the interaction of assigned study medications (irbesartan, amlodipine, and placebo) on progressive renal failure and all-cause mortality were assessed An additional renoprotective effect of irbesartan, independent of achieved SBP, was observed down to 120 mmHg.
Irbesartan Yes
Schjoedt et al. [ Schjoedt et al. [46] 2004 Denmark RCT 63
Patients with type 1 diabetes and DN were treated with losartan, 100 mg once daily, for a mean follow-up period of 35 months.
Aldosterone escape during long-term blockade of the reninangiotensin-aldosterone system is associated with an enhanced decline in GFR in patients with type 1 diabetes and DN.
Losartan Yes
Chan et al. [47] 2004 China RCT 252
Compared losartan (50 mg titrated to 100 mg) to placebo in addition to conventional antihypertensive medications in type 2 diabetic patients with nephropathy.
Losartan conferred significant renal benefits and was well tolerated in Asian patients with type 2 diabetes and clinical nephropathy.
Song et al. [48] 2003 Korea prospective crossover trial 32
Four to 8 mg once-daily dose of candesartan and placebo were alternatively added on ramipril dose of 5 -7.5 mg/day for 16 weeks.
Definite beneficial effects of dual blockade of RAS on proteinuria and TGF-β1 excretion were found in IgA nephropathy patients, which was independent of blood pressurereducing effect.
Dual Yes
Rossing et al. [49] 2003 Denmark After a 12-week stabilization period (control period), 4 mg, once daily, dose of candesartan (combination period) followed by a placebo (placebo period), or vice versa, were administered in addition to the ramipril, for 12 weeks.
The benefit of combination therapy and its antiproteinuric effect was different between IgA and DN over the 12-week trial.
Jacobsen et al. [ Dual blockade of the RAS reduces albuminuria and blood pressure T2D patients with DN responding insufficiently to previous antihypertensive therapy, including ACE inhibitors in recommended doses.
Philips et al. [56] 2001 Belgium RCT 200
The study included 200 patients randomized to receive candesartan 16 mg or lisinopril 20 mg for 12 weeks, followed by 12 weeks of the same monotherapy or a combination treatment.
All three of the treatments are effective, but the dual blockade is respectively 18%, 8 mmHg and 5 mmHg more effective in reducing microalbuminuria, systolic and diastolic blood pressure.
Andersen et al. [57] 2000 Denmark randomized, double-blind crossover trial 16 The patients received losartan 50 mg, losartan 100 mg, enalapril 10 mg, enalapril 20 mg, and placebo in random order.
Losartan represents a valuable new drug in the treatment of hypertension and proteinuria in type 1 diabetic patients with DN.
Losartan Yes
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Grzeszczak et al. [58] 1997 Poland RCT 220
Compared the distribution of PstI melting polymorphism at the ACE locus among NIDDM patients with DN and in patients who, despite long duration of NIDDM, remain without this complication.
The study revealed that PstI sequence differences ("+/= and -") in the ACE gene do not contribute to genetic susceptibility to DN in NIDDM.
PstI No
Strojek et al. [59] 1995 Poland RCT 30
The assessment of plasma renin activity (PRA) and aldosterone (aldo) in type I euglycemic diabetic patients on intensive insulin treatment without autonomic neuropathy.
In euglycemic intensively insulin treated type I diabetic patients without neuropathy presented decreased level of PRA and aldo. Excel. Data extraction included abstractions based on predefined categories as well as qualitative text data (to allow a combination of systematic assessment and depth to be achieved). The collected information included details about the study characteristics, such as aims, participants, study design, methods, outcomes, and treatment/dose measures. Two reviewers carried out data extraction independently and resolved any disagreement by consensus and discussion. Of the 45 datasets included in the metaanalysis, two were crossover study trials and five were prospective studies. Fifteen conducted double-blinded trials, and 23 conducted randomized trials. Data characteristics from the datasets are summarized in Table 1 .
PRA and Aldo No
Risk of bias and strength of evidence
Given that most studies were RCTs, the overall risk of bias was moderate to high and the study quality was fair. The overall magnitude of association was high and there was large heterogeneity between studies. A possible reason for high heterogeneity (I2: 85%>) is that no correlations were made with regards to subgroups or geographical regions in the included studies. The studies included for analysis were conducted in a number of countries (China, Denmark, Germany, Iran, Japan, Korea, Netherlands, Spain, Turkey, and Thailand).
Main findings
To our knowledge, this study presents one of the first systematic reviews and meta-analyses of the evidence for a neutral effect between dual blockade RAAS and DN using data from RCTs and controlled trials. An association (which was non-significant, due to the high heterogeneity) between a dual RAAS blockade and DN was observed; 18 of the 45 datasets revealed that dual therapies were effective among DN patients. The results appear to demonstrate high I2 values with significant associated p-values as well as CI that cross 0. This demonstrates high heterogeneity among the studies and a non-significant effect. 
The effect of combination therapy on albuminuria
There was a decline in albuminuria with dual blockade combination therapy (mean difference: -19.93 mcg/L; 95% CI -50.32 -10.47; I2 = 87.8%, p = 0.000) (Figure 2A ).
The effect of combination therapy on proteinuria
There was a slight but non-significant increase in proteinuria with dual blockade combination therapy (mean difference: 0.19 mg/mmol; 95% CI -2.32 -2.70; I2 = 99.2%, p = 0.000) ( Figure  2B ). There was also a slightly but not significant decrease in GFR (mean difference: -1.11 mL/min; 95% CI -3.00 -0.77; I2 = 95.0%, p = 0.000) with dual blockade combination therapy ( Figure 2C ).
The effect of combination therapy on blood pressure
There was a 1.33 mmHg decrease (mean difference: -1.33, 95% CI -3.70 -1.04; I2 = 95.3%, p = 0.000) in SBP with dual blockade combination therapy ( Figure 2D ), and 1.58 mmHg decrease in DBP (mean difference: -1.58, 95% CI -3.25 -0.14; I2 = 95.0%, p = 0.000) with dual blockade combination therapy ( Figure 2E ). 
Discussion
Based on this review, it is reasonable to postulate that a further reduction in proteinuria, albuminuria, and BP by dual RAAS blockade (or combination therapies) might further decrease disease progression. In this meta-analysis, we found that the effects of combination dual RAAS blockade therapy were neutral for proteinuria and albuminuria among DN patients.
However, dual RAAS blockade was associated with a slight decline in SBP and DBP. This finding is consistent with a review conducted by Elrggal et al. on a number of key clinical trials, which highlighted the dogma that the benefit of a RAAS blockade in DKD are beyond mere adequate blood pressure control.
A number of studies (n = 18), studies combining ACEi and ARB particularly, demonstrate that dual blockade of the RAAS is safe and effective in reducing albuminuria, proteinuria, blood pressure, and urinary markers [22, 32, 34, 35, 37, 39, [41] [42] [43] 45, 48, [49] [50] [51] [52] [54] [55] [56] , as well as provide renal and cardiovascular protection [54] . These studies also suggest that dual blockade of the RAAS is more effective than individual treatments (monotherapies).
Four studies have specifically shown that the combination of ACEi and ARB provides renal and cardiovascular benefits in patients with DN [22, 34, 37, 41] . Both ACEis and ARBs suppress aldosterone secretion; however, with prolonged treatment, aldosterone levels increase, a phenomenon termed "aldosterone escape" [7, 46] . Moreover, there is a secondary increase in renin with either ACEi or ARB therapy. Interestingly, Pohl et al. also suggested an SBP target between 120 and 130 mmHg, in conjunction with blockade of the RAS, in patients with DN [44] .
In contrast, there are also a number of studies (n = 21) which investigated the effect of using monotherapies, and report some benefits and effects on renal outcomes and/or RAAS blockade efficacy among DN patients [16] [17] [18] [19] 21, 24, [26] [27] [28] [29] [30] [31] 33, 38, 40, 46, 47, 53, [57] [58] [59] .
However, these studies do not report significant benefits of these therapies when used in combination. ARBs have also shown to be a more superior and potent treatment option compared to others among DN patients [16, 30] . In six studies, the therapies appeared to have a similar effect or were unable to show any effect or benefit on varied renal outcomes [1, 20, 23, 25, 36, 44] .
Based on the current evidence, many investigators no longer recommend the routine use of dual RAAS blockade for the treatment of hypertension or chronic kidney disease, except for the presence of HF with reduced EF or DN with proteinuria [8] .
Instead of implementing new methods non-selectively, the effort should be directed towards finding specific populations (defined by genetic markers, features of the disease, or other parameters) that will have the most benefit and/or the least risk from any particular treatment regime. The more distant future will probably bring the "tailoring" of the treatment to each individual, and not simply to a group or a disease [9] .
Strengths and Limitations
The primary strength of this meta-analysis is the expansive literature search. However, there are several limitations, mainly stemming from the quality of the included studies, as summarized in Table  1 . A few studies in the review contained a secondary analysis of a study designed to test a different primary hypothesis, and this will inevitably result in some measurement bias and residual confounding. The absence of patient outcome data necessitated the use of surrogate markers (proteinuria and albuminuria) for the primary outcomes. Further research should be conducted on correlating these outcomes to sub-groups or geographical regions. Furthermore, there was likely an underrepresentation of African patients being studied in the included studies. The strength of systematic reviews is that by systematically identifying these limitations, future designs can be improved.
Implications
This review suggests that we should evolve from repeating RCT studies to studies examining causal relationships. The ideal study design could either be a prospective design including patients potentially at high risk for type 2 diabetes mellitus (e.g., positive family history of diabetes); with or without DN, albuminuria or proteinuria; matched for at least positive changes in BP and GFR measured over time. Further secondary analyses are unlikely to contribute further to the field unless there is an adequate assessment of potential confounding factors.
Conclusion
This review contributes to the growing evidence of a moderate but persistent dose-response relationship for the efficacy of RAAS blockade among patients with DN. Based on this study, it appears that dual blockade RAAS (or a combination of therapies) is a neutral treatment for patients with DN presenting with symptoms of albuminuria and/or proteinuria, as other factors must also be considered when recommending therapies for DN patients.
